COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants

COVID-19 vaccine efficacy is threatened by emerging SARS-CoV-2 variants of concern (VOC) with the capacity to evade protective neutralizing antibody responses. We recently developed clinical vaccine candidate COH04S1, a synthetic modified vaccinia Ankara vector (sMVA) co-expressing spike and nucleoc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:iScience 2022-06, Vol.25 (6), p.104457-104457, Article 104457
Hauptverfasser: Wussow, Felix, Kha, Mindy, Faircloth, Katelyn, Nguyen, Vu H., Iniguez, Angelina, Martinez, Joy, Park, Yoonsuh, Nguyen, Jenny, Kar, Swagata, Andersen, Hanne, Lewis, Mark G., Chiuppesi, Flavia, Diamond, Don J.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:COVID-19 vaccine efficacy is threatened by emerging SARS-CoV-2 variants of concern (VOC) with the capacity to evade protective neutralizing antibody responses. We recently developed clinical vaccine candidate COH04S1, a synthetic modified vaccinia Ankara vector (sMVA) co-expressing spike and nucleocapsid antigens based on the Wuhan-Hu-1 reference strain that showed potent efficacy to protect against ancestral SARS-CoV-2 in Syrian hamsters and non-human primates and was safe and immunogenic in healthy volunteers. Here, we demonstrate that intramuscular immunization of Syrian hamsters with COH04S1 and an analogous Beta variant-adapted vaccine candidate (COH04S351) elicits potent cross-reactive antibody responses and protects against weight loss, lower respiratory tract infection, and lung pathology following challenge with major SARS-CoV-2 VOC, including Beta and the highly contagious Delta variant. These results demonstrate efficacy of COH04S1 and a variant-adapted vaccine analog to confer cross-protective immunity against SARS-CoV-2 and its emerging VOC, supporting clinical investigation of these sMVA-based COVID-19 vaccine candidates. [Display omitted] •sMVA-vectored COVID-19 vaccines based on SARS-CoV-2 ancestral virus or Beta variant•Vaccinated hamsters develop antibodies to ancestral virus and variants of concern•Vaccines protect hamsters against ancestral SARS-CoV-2 and Beta and Delta variants•sMVA vectors induce potent cross-protective immunity to SARS-CoV-2 and its variants Biological sciences; Immunology; Virology
ISSN:2589-0042
2589-0042
DOI:10.1016/j.isci.2022.104457